Hot, humid air decontamination of a C-130 aircraft contaminated with spores of two acrystalliferous Bacillus thuringiensis strains, surrogates for Bacillus anthracis

Journal of Applied Microbiology
T L BuhrP J Jackson

Abstract

To develop test methods and evaluate survival of Bacillus thuringiensis kurstaki cry(-) HD-1 and B. thuringiensis Al Hakam spores after exposure to hot, humid air inside of a C-130 aircraft. Bacillus thuringiensis spores were either pre-inoculated on 1 × 2 or 2 × 2 cm substrates or aerosolized inside the cargo hold of a C-130 and allowed to dry. Dirty, complex surfaces (10 × 10 cm) swabbed after spore dispersal showed a deposition of 8-10 log10 m(-2) through the entire cargo hold. After hot, humid air decontamination at 75-80°C, 70-90% relative humidity for 7 days, 87 of 98 test swabs covering 0·98 m(2) , showed complete spore inactivation. There was a total of 1·67 log10 live CFU detected in 11 of the test swabs. Spore inactivation in the 98 test swabs was measured at 7·06 log10 m(-2) . Laboratory test methods for hot, humid air decontamination were scaled for a large-scale aircraft field test. The C-130 field test demonstrated that hot, humid air can be successfully used to decontaminate an aircraft. Transition of a new technology from research and development to acquisition at a Technology Readiness Level 7 is unprecedented.

References

Jul 1, 1979·American Journal of Epidemiology·M R MoserD G Ritter
Oct 1, 1990·The Journal of Applied Bacteriology·U RönnerA Henriksson
Oct 1, 1989·Journal of General Microbiology·T KoshikawaM Torii
Jun 1, 1966·Journal of General Microbiology·W G Murrell, W J Scott
Jan 1, 1981·The American Journal of Dermatopathology·J H Dirckx
Nov 1, 1995·Journal of Bacteriology·H Agaisse, D Lereclus
Aug 1, 1995·Molecular Biotechnology·C Avignone-Rossa, C F Mignone
Jul 3, 1989·Physical Review Letters·F D'OrazioR Gerhardt
Sep 4, 1999·Journal of Applied Microbiology·S CharltonA Moir
May 16, 2002·Journal of Applied Microbiology·E MellyP Setlow
Oct 17, 2002·Canadian Journal of Microbiology·Christine FailleThierry Benezech
May 7, 2003·Applied and Environmental Microbiology·Lyndsay RadnedgeGary L Andersen
May 15, 2003·The Journal of Emergency Medicine·George Sternbach
Dec 19, 2003·The New England Journal of Medicine·Sonja J OlsenScott F Dowell
Mar 6, 2007·Journal of Bacteriology·Jean F ChallacombeThomas S Brettin
Sep 25, 2007·Journal of Bacteriology·William H ColemanPeter Setlow
Nov 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Erik P SundeBertil Halle
Nov 26, 2010·Investigative Genetics·David L GreenbergDavid M Wagner

❮ Previous
Next ❯

Citations

Oct 4, 2016·Journal of Applied Microbiology·Q LiP Setlow
Mar 4, 2017·Letters in Applied Microbiology·A H BishopW J Sellors
Jul 12, 2017·Bioengineered·Sangjin ParkSang Yup Lee
Oct 30, 2016·Applied and Environmental Microbiology·Alistair H Bishop, Helen L Stapleton
Jun 8, 2019·Health Security·Karin LemmerRoland Grunow
Feb 9, 2020·Applied and Environmental Microbiology·Willie TaylorPeter Setlow
Apr 15, 2018·Applied and Environmental Microbiology·Christopher K CoteHenry S Gibbons
Sep 24, 2019·Antibodies·George P AndersonEllen R Goldman
Dec 12, 2020·Journal of Environmental Management·Joseph WoodAnne Mikelonis
Jan 4, 2019·Journal of Environmental Management·Alden C AdrionSang Don Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.